Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burixafor - GPCR Therapeutics

Next Previous
Drug Profile

Burixafor - GPCR Therapeutics

Alternative Names: GP 01; GPC-100; TG-0054; TG-3000

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TaiGen Biotechnology
  • Developer GPCR Therapeutics; TaiGen Biotechnology
  • Class Anti-ischaemics; Eye disorder therapies; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stem cell mobilisation
  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 05 May 2025 Exicure plans a phase I chemosensitisation study for Acute myeloid leukaemia (Second-line therapy or greater) (IV, Infusion)
  • 05 May 2025 GPCR Therapeutics and Exicure complete enrolment in a phase II trial for Stem cell mobilization (Combination therapy) in USA (IV, Infusion) (NCT05561751)
  • 14 Apr 2025 Efficacy data from a phase II trial in Stem cell mobilisation released by GPCR Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top